The  Cannabist reports.

Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the treatment of seizures associated with two specific types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.

“The submission is a significant event,” said Steve Schultz, a GW spokesman.

Read on at  http://www.thecannabist.co/2017/11/03/cbd-epidiolex-fda-nda-gw-pharmaceuticals-pharmaceutical-drug/91562/